Cue Biopharma announces initiation of investigator sponsored trial of CUE-102

Cue Biopharma (CUE) announced the initiation of an investigator sponsored trial in rGBM at the DFCI with the first patient in the trial having been dosed with CUE-102. The trial is a Phase 1b, open-label study of adjuvant CUE-102, the Company’s drug product candidate targeting Wilms’ Tumor 1 protein expressing cancers. The goal of the study is to evaluate the tolerability and clinical activity of CUE-102 in patients with GBM at first recurrence.